Author

Alex Straumann

Quo vadis eosinophils
Quo vadis eosinophils

Alex Straumann

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Alex Straumann

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Alex Straumann  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Research on a shoe string: How to do a research project in a non-university setting
Research on a shoe string: How to do a research project in a non-university setting

Alex Straumann

Medical and dietary treatment of EoE
Medical and dietary treatment of EoE

Alex Straumann

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Alex Straumann  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL

Alex Straumann  et al.

BUDESONIDE ORODISPERSIBLE TABLETS IMPROVE THE ESOPHAGEAL DISTENSIBILITY IN EOSINOPHILIC ESOPHAGITIS: RESULTS FROM SUBSET ANALYSES OF THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED EOS-1 AND EOS-2 TRIALS
BUDESONIDE ORODISPERSIBLE TABLETS IMPROVE THE ESOPHAGEAL DISTENSIBILITY IN EOSINOPHILIC ESOPHAGITIS: RESULTS FROM SUBSET ANALYSES OF THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED EOS-1 AND EOS-2 TRIALS

Alex Straumann  et al.

SEX IMPACTS ENDOSCOPIC AND HISTOLOGICAL DISEASE ACTIVITY BUT NOT SYMPTOMS OR QUALITY OF LIFE IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS OF A NATIONWIDE PROSPECTIVE COHORT STUDY
SEX IMPACTS ENDOSCOPIC AND HISTOLOGICAL DISEASE ACTIVITY BUT NOT SYMPTOMS OR QUALITY OF LIFE IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS OF A NATIONWIDE PROSPECTIVE COHORT STUDY

Alex Straumann  et al.

ODYNOPHAGIA AND RETROSTERNAL PAIN IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS – RATHER INDICATIVE OF DISEASE ACTIVITY THAN SIDE EFFECT OF THERAPY
ODYNOPHAGIA AND RETROSTERNAL PAIN IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS – RATHER INDICATIVE OF DISEASE ACTIVITY THAN SIDE EFFECT OF THERAPY

Alex Straumann  et al.

A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE
A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE

Alex Straumann  et al.

A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

Alex Straumann  et al.

Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults
Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults

Alex Straumann  et al.

Item 1 - 14 / 14
1